The global endoscopic retrograde cholangiopancreatography market size was valued at USD 2.33 billion in 2025 and is projected to grow from USD 2.52 billion in 2026 to USD 4.74 billion by 2034, registering a CAGR of 8.21% during the forecast period from 2026 to 2034. North America dominated the endoscopic retrograde cholangiopancreatography market with a market share of 38.6% in 2025.
Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive medical procedure used to diagnose and treat disorders of the bile ducts, pancreas, and gallbladder. It combines endoscopy and X-ray imaging to detect and manage conditions such as gallstones, bile duct blockages, tumors, and pancreatic diseases. Demand is growing due to the increasing prevalence of gastrointestinal disorders, advancements in endoscopic technology, and the rising preference for minimally invasive treatments.
Download a Free Sample To learn more about this report,
Increasing Adoption of Advanced Therapeutic ERCP Procedures
The endoscopic retrograde cholangiopancreatography market is increasingly shifting toward therapeutic applications for the management of pancreaticobiliary disorders. ERCP is widely used for procedures such as stone removal, biliary drainage, stent placement, and the treatment of ductal obstructions. Advances in endoscopic accessories and therapeutic techniques are supporting more precise interventions and expanding the role of ERCP in specialized gastrointestinal care.
In March 2026, healthcare providers continued advancing therapeutic endoscopic approaches for the management of complex biliary and pancreatic conditions.
Growing Integration of Advanced Imaging and Visualization Technologies
Improvements in endoscopic imaging and visualization are supporting more detailed assessment of the biliary and pancreatic ductal systems during gastrointestinal procedures. Enhanced visualization technologies can assist physicians in identifying abnormalities and guiding therapeutic interventions. The growing emphasis on improved procedural visualization is contributing to the development of more advanced ERCP systems and associated technologies.
In July 2026, medical technology providers continued advancing imaging and visualization capabilities supporting complex gastrointestinal endoscopy procedures.
Rising Incidence of Pancreaticobiliary Disorders and Biliary Obstruction
The increasing need for diagnosis and treatment of conditions involving the bile ducts and pancreas is supporting demand for ERCP procedures. Disorders such as bile duct stones, biliary strictures, pancreatic duct abnormalities, and other obstructive conditions can require specialized endoscopic intervention. The growing clinical burden of pancreaticobiliary disorders therefore remains an important driver of the endoscopic retrograde cholangiopancreatography market.
In April 2026, healthcare providers continued expanding specialized gastrointestinal services for patients requiring pancreaticobiliary diagnosis and treatment.
Risk of Procedure-Related Complications and Requirement for Specialized Expertise
ERCP is a technically complex procedure that can involve complications, including post-procedure pancreatitis, bleeding, infection, and perforation. Performing therapeutic interventions safely requires specialized equipment and experienced healthcare professionals. Concerns regarding procedural risks and the limited availability of highly trained specialists can therefore restrict broader adoption of ERCP services.
In June 2026, healthcare organizations continued emphasizing specialized training and safety practices for complex gastrointestinal endoscopy procedures.
Expansion of ERCP Services in Emerging Healthcare Markets
Improving healthcare infrastructure and expanding access to specialized gastrointestinal services are creating opportunities for ERCP technology and service providers in developing healthcare markets. Growing investments in hospitals, endoscopy facilities, and specialist training can support wider availability of advanced pancreaticobiliary procedures. The expansion of specialized digestive healthcare infrastructure therefore represents an important growth opportunity for the ERCP market.
In August 2026, healthcare systems continued expanding investments in specialized endoscopy capabilities and gastrointestinal treatment infrastructure.
Maintaining Consistent Procedural Quality Across Healthcare Facilities
ERCP outcomes can vary depending on physician experience, equipment availability, procedural techniques, and institutional protocols. Ensuring consistent procedural quality and maintaining appropriate standards across hospitals and endoscopy centers can be challenging, particularly as advanced gastrointestinal services expand into new healthcare settings. Supporting standardized training, quality monitoring, and procedural practices therefore remains a significant challenge for the endoscopic retrograde cholangiopancreatography market.
In August 2026, healthcare organizations continued emphasizing standardized quality-management practices for advanced gastrointestinal endoscopy services.
Endo Therapy Devices Segment Dominated the Market with 43.8% Share in 2025
The endo therapy devices segment dominated the global endoscopic retrograde cholangiopancreatography market with a 43.8% share in 2025. These devices are widely used during ERCP procedures for stone removal, stent placement, tissue sampling, and other therapeutic interventions. The growing preference for minimally invasive procedures and the increasing number of biliary and pancreatic disorders continue to support the segment's leading position.
The endoscopes and visualization systems segments are also growing steadily. Endoscopes remain essential for accessing and examining the biliary and pancreatic ducts, while advanced visualization systems help physicians perform procedures with greater accuracy and improved image quality. Their continuous technological improvements are supporting wider adoption across healthcare facilities.
The energy devices and others segments also continue to expand as hospitals adopt advanced equipment for precise tissue cutting, coagulation, and other specialized ERCP procedures. Ongoing innovation in endoscopic technologies is expected to support growth across all product categories.
Request Customizationto receive a tailored report.
Biliary Stenting Segment Dominated the Market with 24.8% Share in 2025
The biliary stenting segment dominated the global endoscopic retrograde cholangiopancreatography market with a 24.8% share in 2025. Biliary stenting is widely performed to relieve bile duct blockages caused by gallstones, tumors, or strictures. The increasing number of biliary diseases and the growing preference for minimally invasive treatment continue to drive demand for this procedure.
The biliary sphincterotomy, pancreatic duct stenting, and biliary dilatation segments are also witnessing steady growth. These procedures are commonly performed to improve bile flow, remove stones, and treat narrowing of the bile ducts. Their effectiveness in managing complex pancreatic and biliary conditions continues to support their adoption.
The pancreatic sphincterotomy, pancreatic duct dilation, and endoscopic retrograde procedures also continue to grow as physicians increasingly rely on advanced ERCP techniques for accurate diagnosis and treatment. Improvements in endoscopic devices and procedural techniques are expected to support growth across all procedure segments.
Hospitals Segment Dominated the Market with 74.6% Share in 2025
The hospitals segment dominated the global endoscopic retrograde cholangiopancreatography market with a 74.6% share in 2025. Hospitals perform the majority of ERCP procedures because they have specialized gastroenterologists, advanced imaging equipment, and comprehensive surgical facilities to manage complex biliary and pancreatic conditions. Rising patient admissions and increasing availability of advanced endoscopy units continue to strengthen this segment.
The outpatient facilities segment is also growing steadily as more minimally invasive ERCP procedures are being performed in specialized outpatient centers. These facilities offer shorter recovery times, lower treatment costs, and greater convenience for eligible patients, making them an increasingly attractive option.
Growing awareness of early diagnosis, advances in endoscopic technologies, and the increasing preference for minimally invasive gastrointestinal procedures are expected to support demand across both hospitals and outpatient facilities.
Speak to an Analystto discuss market opportunities.
North America endoscopic retrograde cholangiopancreatography market accounted for 38.6% of the global market, reaching USD 0.90 billion in 2025, and is projected to grow at a CAGR of 7.4% during the forecast period. The market is growing steadily because of the increasing number of gastrointestinal disorders, rising demand for minimally invasive procedures, and wider adoption of advanced endoscopy systems. Strong healthcare infrastructure and ongoing technological advancements are also supporting market growth.
The U.S. market was valued at USD 0.77 billion in 2025, making it the largest contributor in North America. Growing demand for minimally invasive gastrointestinal procedures, increasing prevalence of pancreatic and biliary disorders, and continuous investment in advanced endoscopy technologies continue to drive market growth.
Canada's market reached USD 0.13 billion in 2025. Rising healthcare spending, increasing awareness of digestive diseases, and expanding access to advanced diagnostic and therapeutic procedures continue to support steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe endoscopic retrograde cholangiopancreatography market accounted for 27.2% of the global market, reaching USD 0.63 billion in 2025, and is expected to register a CAGR of 7.1% during the forecast period. Increasing cases of biliary and pancreatic diseases, growing preference for minimally invasive treatments, and well-developed healthcare systems are supporting market growth. Continued investment in advanced endoscopic equipment is also contributing to regional expansion.
Germany's market accounted for USD 0.18 billion in 2025. Strong healthcare infrastructure, increasing use of advanced endoscopy systems, and growing demand for gastrointestinal procedures continue to support market growth.
The UK market was valued at USD 0.13 billion in 2025. Rising awareness of digestive health, expanding endoscopy services, and increasing adoption of minimally invasive procedures continue to contribute to market growth.
Asia Pacific endoscopic retrograde cholangiopancreatography market accounted for 23.8% of the global market, valued at USD 0.55 billion in 2025, and is projected to register a CAGR of 9.2% during the forecast period. Improving healthcare infrastructure, increasing diagnosis of gastrointestinal disorders, and rising demand for advanced endoscopic procedures are driving market growth across the region. Expanding healthcare access and growing investments in medical technology are also creating new opportunities.
Japan's market generated USD 0.10 billion in 2025. An aging population, advanced healthcare facilities, and increasing demand for minimally invasive gastrointestinal treatments continue to support market growth.
China's market accounted for USD 0.29 billion in 2025, representing the largest share within Asia Pacific. Rising healthcare investments, increasing prevalence of digestive diseases, and expanding hospital infrastructure continue to drive market growth.
Latin America endoscopic retrograde cholangiopancreatography market accounted for 6.1% of the global market, reaching USD 0.14 billion in 2025, and is projected to grow at a CAGR of 7.6% during the forecast period. Improving healthcare services, increasing awareness of gastrointestinal diseases, and expanding access to advanced endoscopic procedures are supporting market growth across the region.
Brazil's market reached USD 0.07 billion in 2025. Rising healthcare investments, growing availability of endoscopy services, and increasing demand for minimally invasive treatments continue to create growth opportunities.
Middle East & Africa endoscopic retrograde cholangiopancreatography market accounted for 4.3% of the global market, totaling USD 0.10 billion in 2025, and is anticipated to grow at a CAGR of 7% during the forecast period. Growing healthcare investment, improving access to specialized gastrointestinal care, and increasing adoption of advanced endoscopy technologies are supporting market growth across the region.
The UAE market was valued at USD 0.04 billion in 2025. Government investment in advanced healthcare facilities, increasing demand for minimally invasive procedures, and expanding gastroenterology services continue to support market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
North America Clinical Trial Imaging Market Size, Share, and Forecast 2034
Europe Clinical Trial Imaging Market Analysis, Trends, Forecast Up to 2034
Asia Pacific Clinical Trial Imaging Market Size, Share and Forecast to 2034
India Pharmaceutical Stability and Storage Services Market Size, Share & Trends | Industry Report, 2034
Healthcare Regulatory Affairs Outsourcing Market Size, Share, 2034
Facial Fat Transfer Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com